This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 2 of 16

Biotech's Next Big Thing: Aveo

By Adam Feuerstein

TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.

09:34AM 04/25/13

The Next Big Thing In Biotech: Titan

By Adam Feuerstein

Titan Pharmaceuticals is the next big thing in biotech, Adam Feuerstein, Sr. Columnist for TheStreet, tells Gregg Greenberg

12:02PM 03/14/13

The Next Big Thing In Biotech: Onyx

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg why Onyx Pharmaceuticals is the next big thing in biotech.

01:11PM 03/07/13

The Next Big Thing In Biotech: DepoMed

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist at TheStreet, says DepoMed is the next big thing in biotech.

09:42AM 02/28/13

The Next Big Thing In Biotech: BIO CEO Conference

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, says the BIO CEO Conference is the next big thing in biotech.

11:38AM 02/07/13

The Next Big Thing In Biotech: Gilead

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, says Gilead Sciences is the next big thing in biotech.

07:21AM 02/01/13

The Next Big Thing in Biotech: Celgene

By Adam Feuerstein

Senior columnist Adam Feuerstein says Celgene is the next big thing in biotech.

05:30AM 01/18/13

The Next Big Thing in Biotech: J.P. Morgan Conference

By Adam Feuerstein

Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.

05:00AM 01/04/13

The Next Big Thing In Biotech: 2013 Outlook

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, offers his outlook for the best and worst biotech stock in the coming year.

05:30AM 12/21/12

The Next Big Thing in Biotech: FDA Decisions

By Adam Feuerstein

Senior columnist Adam Feuerstein says three big FDA drug approval decisions are the next big things to watch in biotech.

05:30AM 12/14/12

Page 2 of 16

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs